Research programme: Klebsiella and Pseudomonas vaccines - Affinivax
Alternative Names: MAPS Klebsiella and Pseudomonas vaccines - AffinivaxLatest Information Update: 28 May 2024
At a glance
- Originator Affinivax
- Developer Affinivax; Astellas Pharma
- Class Conjugate vaccines; Pseudomonas vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Klebsiella infections; Pseudomonal infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Klebsiella-infections(Prevention) in Japan
- 28 May 2024 No recent reports of development identified for preclinical development in Klebsiella-infections(Prevention) in USA
- 28 May 2024 No recent reports of development identified for preclinical development in Pseudomonal-infections(Prevention) in Japan